Literature DB >> 24818984

EASL recommendations on treatment of hepatitis C 2014.

.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24818984     DOI： 10.1016/j.jhep.2014.05.001

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  76 in total

Review 1.  Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.

Authors:  Juan-Ramón Larrubia; Elia Moreno-Cubero; Joaquín Miquel; Eduardo Sanz-de-Villalobos
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 2.  Acute HCV in HIV-infected MSM: modes of acquisition, liver fibrosis, and treatment.

Authors:  Emma Kaplan-Lewis; Daniel Seth Fierer
Journal:  Curr HIV/AIDS Rep       Date:  2015-09       Impact factor: 5.071

Review 3.  HCV Treatments and Their Integration Into Rheumatology.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Curr Rheumatol Rep       Date:  2015-08       Impact factor: 4.592

4.  Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients.

Authors:  Sylvie Larrat; Om Kulkarni; Jean-Baptiste Claude; Réjane Beugnot; Michaël G B Blum; Katia Fusillier; Julien Lupo; Pauline Tremeaux; Agnès Plages; Alice Marlu; Hervé Duborjal; Anne Signori-Schmuck; Olivier Francois; Jean-Pierre Zarski; Patrice Morand; Vincent Leroy
Journal:  J Clin Microbiol       Date:  2014-11-19       Impact factor: 5.948

Review 5.  Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis.

Authors:  Christoph Roderburg; Frank Tacke; Christian Trautwein
Journal:  Visc Med       Date:  2016-04-05

Review 6.  Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6.

Authors:  Vasilios Papastergiou; Stylianos Karatapanis
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

Review 7.  Hepatitis C and kidney disease: An overview and approach to management.

Authors:  Ahmad Najib Azmi; Soek-Siam Tan; Rosmawati Mohamed
Journal:  World J Hepatol       Date:  2015-01-27

8.  Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients.

Authors:  Youssef K Ahmad; Salwa Tawfeek; Mohamed Sharaf-Eldin; Hassan E Elbatea; Abdelrahman Kobtan; Ferial El-Kalla; Rehab Badawi; Sherief Abd-Elsalam
Journal:  Hosp Pharm       Date:  2017-04

9.  Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.

Authors:  Michael Gschwantler; Hermann Laferl; Wolfgang Vogel; Wolfgang Korak; Stephan Moser; Harald Hofer; Bernhard Bauer; Michael Schleicher; Barbara Bognar; Martin Bischof; Rudolf Stauber; Andreas Maieron; Peter Ferenci
Journal:  Wien Klin Wochenschr       Date:  2017-09-12       Impact factor: 1.704

Review 10.  Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.

Authors:  Pankaj Puri; Anil C Anand; Vivek A Saraswat; Subrat K Acharya; Shiv K Sarin; Radha K Dhiman; Rakesh Aggarwal; Shivaram P Singh; Deepak Amarapurkar; Anil Arora; Mohinish Chhabra; Kamal Chetri; Gourdas Choudhuri; Vinod K Dixit; Ajay Duseja; Ajay K Jain; Dharmesh Kapoor; Premashis Kar; Abraham Koshy; Ashish Kumar; Kaushal Madan; Sri P Misra; Mohan V G Prasad; Aabha Nagral; Amarendra S Puri; R Jeyamani; Sanjiv Saigal; Samir Shah; Praveen K Sharma; Ajit Sood; Sandeep Thareja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2014-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.